10-Q: Profusa Q1 2026 Financial and Operational Update

Profusa reports a $3.5 million net loss for Q1 2026 while navigating Nasdaq listing challenges and securing new capital.

Summary

• Reported a net loss of $3.5 million for the three months ended March 31, 2026, compared to a $2.7 million loss in the same period of 2025.
• Operating expenses rose to $4.0 million, driven by increased R&D and administrative costs.
• Working capital deficit stands at approximately $28.4 million as of March 31, 2026.
• Successfully obtained forgiveness for a $1.4 million PPP loan, recorded as a gain.
• Terminated Bitcoin treasury strategy, selling 16.51 Bitcoins for $1.2 million.
• Transferred listing to The Nasdaq Capital Market effective May 15, 2026, following compliance relief.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a high-risk situation due to the going concern warning, severe liquidity constraints, and reliance on dilutive financing to survive.

Positives

• Forgiveness of $1.4 million PPP loan significantly improved the balance sheet.
• Secured additional financing capacity through amendments to the PIPE Subscription Agreement, providing up to $12.2 million in potential funding.
• Entered into a strategic know-how license agreement with the Mayo Clinic for continuous oxygen measurement technology.
• Successfully negotiated the conversion of $1.9 million in related-party debt into common stock, reducing near-term cash obligations.

Negatives

• Net loss increased to $3.5 million from $2.7 million year-over-year.
• Cash position significantly depleted to $0.4 million as of March 31, 2026, from $1.8 million at year-end 2025.
• Material weaknesses in internal control over financial reporting persist, specifically regarding segregation of duties and technical accounting expertise.
• Significant reliance on external financing to maintain operations and avoid insolvency.

Risks

• Substantial doubt exists regarding the ability to continue as a going concern within one year.
• Ongoing compliance risks with Nasdaq listing standards despite recent relief.
• High cash burn rate relative to current liquidity levels.
• Dependence on successful regulatory approval for Lumee Glucose and renewal of CE Mark for Lumee Oxygen.
• Potential for significant shareholder dilution due to future equity-based financing.

Future Outlook

Management expects to continue incurring substantial losses while focusing on R&D, clinical trials, and commercialization of the Lumee Oxygen and Lumee Glucose platforms. The company plans to utilize existing financing facilities and potential future capital raises to support operations.

Management Comments

• Management acknowledges substantial doubt regarding the company's ability to continue as a going concern.
• The company is prioritizing commercialization efforts in Europe and the U.S. while managing liquidity through debt and equity financing.

Industry Context

StockSavvy.ai notes that Profusa operates in the highly competitive digital health and medical device sector, where cash-intensive R&D and regulatory hurdles are standard. The company's struggle to maintain Nasdaq compliance and its reliance on dilutive financing are common challenges for early-stage clinical companies in this space.

Comparison to Industry Standards

• The company's reliance on equity lines of credit and convertible debt is typical for pre-revenue or early-commercial stage medical technology firms.
• The transition to The Nasdaq Capital Market is a standard move for companies struggling to meet the higher market value requirements of the Global Market.

Corporate Governance

Legal Proceedings

• Accrued $0.1 million for a vendor breach of contract judgment.
• Accrued $0.2 million for a former employee wage claim.

Related Party Transactions

• Significant debt held by related parties including Tasly and NorthView Sponsor I, LLC.
• Conversion of related-party promissory notes into common stock.

Stakeholder Impact

• Shareholders face significant dilution from ongoing equity-based financing and debt conversions.
• Creditors are involved in ongoing debt restructuring and conversion agreements.

Next Steps

• Obtain stockholder approval for a reverse stock split by June 5, 2026.
• Demonstrate compliance with minimum bid price and equity requirements by July 6, 2026.
• Continue R&D and clinical trials for Lumee Glucose.
• Pursue commercialization of Lumee Oxygen in Europe.

Key Dates

Recommendation

The company faces severe liquidity issues, a going concern warning, and significant dilution risks, making it a high-risk investment unsuitable for most portfolios.

Keywords

Profusa, biotech, continuous glucose monitoring, medical devices, Nasdaq, going concern, capital raise